| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 6 securities · passive | ||||||
|
Forte Biosciences, Inc.
13G/A
FBRX · 34962G208
|
0% |
11/13/2026
Event 9/30/2026
|
||||
|
DBV Technologies S.A.
13G/A
DBVT · 23306J309
|
4.8% |
11/13/2026
Event 9/30/2026
|
||||
|
Corbus Pharmaceuticals Holdings, Inc.
13G
CRBP · 21833P301
|
8.6% |
11/13/2026
Event 9/30/2026
|
||||
|
Context Therapeutics Inc.
13G/A
CNTX · 21077P108
|
1.4% |
8/14/2026
Event 6/30/2026
|
||||
|
Climb Bio, Inc.
13G/A
CLYM · 28658R106
|
0% |
8/14/2026
Event 6/30/2026
|
||||
|
Compass Therapeutics, Inc.
13G/A
CMPX · 20454B104
|
4.1% |
8/12/2025
Event 6/30/2025
|
||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.